PSORIASIS
Centocor And Janssen Cilag Submit Applications Requesting Approval Of Ustekinumab In The U.S. And Europe For Treatment Of Severe Plaque Psoriasis
Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.
http://www.medicalnewstoday.com/articles/91209.php
|
